MERAIODE: A Phase II Redifferentiation Trial with Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>RAS</i> Mutated Differentiated Thyroid Cancer-Reference-Cited by-同舟云学术

MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

Published:2023-07-26 Issue: Volume: Page:
ISSN:1050-7256
Container-title:Thyroid®
language:en
Short-container-title:Thyroid®

Author:

Leboulleux Sophie¹²,Benisvy Daniele³,Taieb David⁴,Attard Marie⁵,Bournaud Claire⁶,Terroir-Cassou-Mounat Marie¹⁷,Lacroix Ludovic⁸⁹,Anizan Nadege¹¹⁰^ORCID,Schiazza Aurelie³,Garcia Marie Eve¹¹,Ghuzlan Abir Al⁸,Lamartina Livia¹,Schlumberger Martin¹,Godbert Yann¹²,Borget Isabelle¹³

Affiliation:

1. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.

2. Department of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Hôpitaux Universitaires de Genève, Geneve, Switzerland.

3. Department of Nuclear Medicine, CLCC Antoine Lacassagne, Nice, France.

4. Department of Nuclear Medicine, CHU de La Timone, Marseille, France.

5. Department of Imaging Gustave Roussy and University Paris Saclay, Villejuif, France.

6. Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon, France.

7. Department of Nuclear Medicine UICT Oncopole, CLCC Institut Claudius Regaud, Toulouse, France.

8. Department of Medical Biology and Pathology, Gustave Roussy and University Paris Saclay, Villejuif, France.

9. AMMICa UAR3655/US23, Gustave Roussy, Villejuif, France.

10. Department of Physics, Gustave Roussy and University Paris Saclay, Villejuif, France.

11. Department of Oncology, CHU de La Timone, Marseille, France.

12. Department of Oncology and Department of Nuclear Medicine, CLCC Institut Bergonié, Bordeaux, France.

13. Department of Epidemiology and Biostatistics, Gustave Roussy and University Paris Saclay, Villejuif, France.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2023.0240

Reference10 articles.

1. Biologic and Clinical Perspectives on Thyroid Cancer

2. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

3. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

4. Integrated Genomic Characterization of Papillary Thyroid Carcinoma

5. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thyroid Cancer;JAMA;2024-02-06

2. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers;Thyroid®;2024-01-01

3. Clinical and Surgical Year in Review;Thyroid®;2024-01-01

4. Genomic alterations in thyroid cancer: biological and clinical insights;Nature Reviews Endocrinology;2023-12-04

5. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine-Refractory RAS-Mutated Differentiated Thyroid Cancers;Clinical Thyroidology®;2023-08-01